Angiotensin Converting Enzyme Inhibitors Market
Angiotensin Converting Enzyme (ACE) Inhibitors Market Size, Share & Industry Analysis, By Type (Captopril, Enalapril, Lisinopril, Ramipril, Others), By Application (Hypertension, Heart Failure, Diabetic Nephropathy, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) - Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Market Overview:
The global Angiotensin Converting Enzyme (ACE) Inhibitors Market is projected to grow at a CAGR of 3.5% from 2024 to 2031. The market value is expected to increase from USD XX billion in 2024 to USD YY billion by 2031. North America currently dominates the market, followed closely by Europe. Key metrics include the rising prevalence of cardiovascular diseases, increasing geriatric population, and growing awareness about the importance of blood pressure management. The market is experiencing steady growth due to the expanding indications for ACE inhibitors and their proven efficacy in treating various cardiovascular conditions.
Market Dynamics:
Market Trend: Combination therapies gaining traction for improved cardiovascular outcomes
The market for ACE inhibitors is shifting significantly towards combination therapy, in which these drugs are used with other cardiovascular medications to improve efficacy and patient outcomes. This trend is being pushed by accumulating evidence demonstrating the synergistic effects of mixing ACE inhibitors with calcium channel blockers or diuretics. Combination medications have various advantages, including better blood pressure control, fewer side effects, and higher patient compliance due to streamlined dose regimens. Pharmaceutical companies are responded to this trend by creating fixed-dose combination treatments that include ACE inhibitors and other complementing medications in a single pill. This method not only improves treatment outcomes, but it is also more convenient for patients, especially those with numerous comorbidities who require complex prescription regimens.
Market Driver: Rising prevalence of cardiovascular diseases and hypertension fueling demand for ACE inhibitors
The growing global burden of cardiovascular diseases (CVDs) and hypertension is a major driver of the ACE inhibitor market. According to the World Health Organisation, cardiovascular diseases are the leading cause of mortality worldwide, killing an estimated 17.9 million people each year. Over 1 billion people worldwide suffer with hypertension, a major risk factor for cardiovascular disease. ACE inhibitors have demonstrated efficacy in treating hypertension and lowering the risk of cardiovascular events, making them an essential component of CVD therapy. The growing knowledge of the importance of blood pressure control in preventing heart attacks, strokes, and kidney damage is driving up the use of ACE inhibitors. Furthermore, the growing senior population, which is more prone to cardiovascular problems, is driving up demand for these treatments. As healthcare systems around the world focus on preventative care and early intervention in CVDs, the usage of ACE inhibitors as a first-line therapy option is projected to increase dramatically.
Market Restraint: Patent expirations and generic competition impacting market revenue
Patents for several important ACE inhibitors have expired, resulting in increasing generic competition, posing a significant risk to revenue growth in the industry. Generic versions of prominent ACE inhibitors are often priced far lower than their branded counterparts, resulting in price erosion and smaller profit margins for pharmaceutical companies. This tendency has had a particularly strong impact on established market competitors who rely on revenue from branded ACE inhibitors. The availability of low-cost generic alternatives has also altered prescribing trends, with healthcare professionals and insurance companies frequently preferring generic options to cut treatment costs. While this trend benefits patients by increasing access to low-cost drugs, it poses a challenge for companies that spend in research and development of new ACE inhibitor formulations or combination therapies.
Segment Overview:
Lisinopril dominates the ACE inhibitors market due to its efficacy, long-acting formulation, and broad range of indications.
Lisinopril has emerged as the dominant sector in the ACE inhibitors market, accounting for a sizable portion of total market revenue. This dominance can be due to a variety of variables, including its once-daily dosing regimen, demonstrated efficacy in the treatment of hypertension and heart failure, and well-established safety profile. Lisinopril is commonly used as a first-line treatment for hypertension, as well as to treat heart failure and diabetic nephropathy.
Lisinopril is particularly popular among healthcare practitioners because of its long-acting formulation, which promotes patient compliance and guarantees stable blood pressure control over 24 hours. Additionally, Lisinopril has been shown to reduce proteinuria in diabetic individuals with kidney disease, broadening its usage beyond hypertension control.
Recent research have strengthened Lisinopril's market position. For example, studies published in the Journal of the American Heart Association demonstrated the drug's ability to reduce the incidence of recurrent stroke in hypertensive individuals. These data continue to support the widespread usage of Lisinopril in a variety of patient categories.
The retail pharmacy segment has played an important role in driving Lisinopril use. Many drugstore chains have created medication therapy management programs that involve patient education on the safe use of ACE inhibitors, with a particular emphasis on Lisinopril due to its popularity. Furthermore, the availability of low-cost generic versions of Lisinopril has made it a desirable alternative for both patients and healthcare systems seeking to reduce expenses without sacrificing efficacy.
Regional Outlook:
North America leads the ACE inhibitors market, driven by high prevalence of cardiovascular diseases and advanced healthcare infrastructure.
North America, notably the United States, dominates the global ACE inhibitors market. Several reasons contribute to this dominance, including the region's high prevalence of hypertension and cardiovascular disease, a well-established healthcare infrastructure, and favourable payment rules for chronic illness management.
The presence of large pharmaceutical companies, as well as their substantial research and development operations in cardiovascular therapies, reinforces the region's market leadership. These businesses are constantly investing in creating better formulations and combination medicines involving ACE inhibitors.
Recent advancements in the North American market include a greater emphasis on personalised medicine techniques in cardiovascular treatment. Healthcare professionals are increasingly personalising ACE inhibitor prescriptions to specific patients' features, including genetic markers that may influence drug response.
Key statistics emphasise the importance of the North American market. According to the Centres for Disease Control and Prevention (CDC), around 47% of individuals in the United States have hypertension, indicating a large patient base for ACE inhibitors. Furthermore, heart disease remains the top cause of mortality in the United States, emphasising the continuous need for cardiovascular drugs such as ACE inhibitors.
Canada has made a substantial contribution to the region's market growth. The Canadian Hypertension Society's guidelines, which emphasise the use of ACE inhibitors in hypertension management, have altered prescribing patterns throughout the country. Furthermore, government attempts to improve cardiovascular health outcomes have encouraged the widespread use of ACE inhibitors in both primary and secondary prevention methods.
Competitive Intelligence:
The ACE inhibitors industry includes both established pharmaceutical businesses and generic medication makers. Product efficacy, safety profile, cost, and brand awareness are the primary driving forces behind market competition. Key players are focussing on extending their product portfolios by researching and developing novel formulations and combination medicines.
Market leaders have built robust distribution networks and long-term partnerships with healthcare providers, giving them a competitive advantage. However, the introduction of generic versions of prominent ACE inhibitors has increased competition and placed pressure on pricing tactics.
Recent trends in the competitive landscape include a greater emphasis on creating fixed-dose combination medicines that mix ACE inhibitors with other cardiovascular drugs. These combination medicines are intended to promote patient compliance and provide more complete cardiovascular protection.
In terms of market share, the top five competitors account for around 46-47% of the global ACE inhibitor market. These companies have maintained their positions by leveraging strong brand recognition, continual innovation, and strategic connections with healthcare organisations.
Financial research of important participants shows that, while ACE inhibitor revenue growth has slowed due to generic competition, several businesses are compensating by focussing on newer, patent-protected combo medicines. Companies are also extending their presence in emerging areas to capitalise on the increased demand for cardiovascular drugs in these regions.
Analyst Opinion:
The ACE inhibitors market, while established, nevertheless offers prospects for growth and innovation. Personalised medicine methods and the development of more tailored medicines based on individual patient features and genetic profiles will be key to the market's future.
One unique trend to keep an eye on is the possible growth of ACE inhibitor indications beyond cardiovascular illness. Emerging research suggests that these medications may have benefits in illnesses like cognitive decline and some types of cancer. If validated, these potential applications could create major new commercial prospects for ACE inhibitors.
Major Players:
-
Pfizer Inc.
-
Novartis AG
-
Merck & Co., Inc.
-
AstraZeneca plc
-
Jhonson & Johnson Services, Inc.
-
Sanofi S.A.
-
Bristol-Myers Squibb Company
-
Bayer AG
-
Boehringer Ingelheim International GmbH
-
Takeda Pharmaceutical Company Limited
Key Developments:
-
In April 2024, Novartis introduces a novel fixed-dose combination medicine that includes an ACE inhibitor for better hypertension treatment.
-
February 2024: AstraZeneca announces positive findings from a large-scale clinical trial examining the long-term cardiovascular benefits of its ACE inhibitor in patients with numerous risk factors.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope & Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking -- Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies list by Country) (Premium)
5. COMPANY PROFILES
5.1. Pfizer Inc.
5.2. Novartis AG
5.3. Merck & Co., Inc.
5.4. AstraZeneca plc
5.5. Jhonson & Johnson Services, Inc.
5.6. Sanofi S.A.
5.7. Bristol-Myers Squibb Company
5.8. Bayer AG
5.9. Boehringer Ingelheim International GmbH
5.10. Takeda Pharmaceutical Company Limited (*LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Combination therapies gaining traction for improved cardiovascular outcomes
6.1.2. Personalized medicine approaches in ACE inhibitor prescribing
6.1.3. Expansion of ACE inhibitors' indications beyond cardiovascular diseases
6.2. Market Drivers
6.2.1. Rising prevalence of cardiovascular diseases and hypertension fueling demand for ACE inhibitors
6.2.2. Increasing geriatric population susceptible to cardiovascular issues
6.2.3. Growing awareness about the importance of blood pressure management
6.3. Market Restraints
6.3.1. Patent expirations and generic competition impacting market revenue
6.3.2. Side effects associated with long-term use of ACE inhibitors
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
7.1. Captopril
7.2. Enalapril
7.3. Lisinopril
7.4. Ramipril
7.5. Others
8. BY APPLICATION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
8.1. Hypertension
8.2. Heart Failure
8.3. Diabetic Nephropathy
8.4. Others
9. BY DISTRIBUTION CHANNEL (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
9.1. Hospital Pharmacies
9.2. Retail Pharmacies
9.3. Online Pharmacies
10. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
10.1. North America
10.1.1. United States
10.1.2. Canada
10.1.3. Mexico
10.2. South America
10.2.1. Brazil
10.2.2. Argentina
10.2.3. Rest of South America
10.3. Europe
10.3.1. Germany
10.3.2. United Kingdom
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Russia
10.3.7. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Australia
10.4.5. South Korea
10.4.6. Rest of Asia-Pacific
10.5. Middle-East
10.5.1. UAE
10.5.2. Saudi Arabia
10.5.3. Turkey
10.5.4. Rest of Middle East
10.6. Africa
10.6.1. South Africa
10.6.2. Egypt
10.6.3. Rest of Africa
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
By Type:
- Captopril
- Enalapril
- Lisinopril
- Ramipril
- Others
By Application:
- Hypertension
- Heart Failure
- Diabetic
- Nephropathy
- Others
By Distribution Channel:
- Hospital
- Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511